View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Market Data
November 19, 2021

Type 1 Diabetes (Juvenile Diabetes) accounts for 8.4% share of global Metabolic Disorders clinical trial activity in 2020

By Carmen

Type 1 Diabetes (Juvenile Diabetes) accounted for an 8.4% share of the global clinical trials within the Metabolic Disorders therapy area in 2020, registering an increase of 0.3% when compared with the last ten-year average of 8.1% share, according to GlobalData.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Non-industry sponsored trials outnumber industry sponsored trials for Type 1 Diabetes (Juvenile Diabetes)

Industry sponsored trials held a 48.4% share of all the clinical trials for Type 1 Diabetes (Juvenile Diabetes) indication in 2020, registering an increase of 3.3% when compared with the ten-year average of 45.1%. Non-industry sponsored trials accounted for a 51.6% share in 2020, marking a decrease of 3.3% over the ten-year average of 54.9%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top regions of industry sponsored Type 1 Diabetes (Juvenile Diabetes) trials

Europe was the top region for industry sponsored Type 1 Diabetes (Juvenile Diabetes) trials, accounting for a 43.8% share in 2020, when compared with the five-year average of 48.4% and ten-year average of 50.1%.

North America was at the second position with a 35.4% share in 2020, over the five-year average of 39.2% and ten-year average of 41.6%, followed by Asia-Pacific with a 31.3% share in 2020, as against five-year and ten-year averages of 30.0% and 25.8% respectively.

Middle East and Africa stood fourth with an 8.3% share in 2020, compared with the five-year average of 7.2% and ten-year average of 8.4%, followed by South and Central America with a 0.0% share in 2020, over five-year and ten-year averages of 5.1% and 5.0% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

The US was the top country for industry sponsored Type 1 Diabetes (Juvenile Diabetes) trials, accounting for a 33.3% share in 2020, as against the five-year average of 35.4% and ten-year average of 38.8%.

Germany held a 16.7% share in 2020, over the five-year average of 30.0% and ten-year average of 32.2%, followed by Japan with a 10.4% share in 2020, compared with the five-year and ten-year averages of 7.4% and 7.4% respectively.

China held a 10.4% share in 2020, as against the five-year average of 6.7% and ten-year average of 4.3%.

Russia held a 10.4% share in 2020, over the five-year and ten-year averages of 11.7% and 9.0% respectively.

Top regions of non-industry sponsored Type 1 Diabetes (Juvenile Diabetes) trials

North America was the top region for non-industry sponsored Type 1 Diabetes (Juvenile Diabetes) trials, accounting for a 42.4% share in 2020 when compared with the five-year average of 35.2% and ten-year average of 35.3%.

Asia-Pacific was at the second position with a 27.1% share in 2020, over the five-year and ten-year averages of 23.0% and 21.8% respectively, followed by Europe with a 25.4% share in 2020, as against the five-year average of 32.9% and ten-year average of 35.4%.

Middle East and Africa stood at the fourth position with a 5.1% share in 2020, compared with the five-year average of 10.5% and ten-year average of 9.7%, followed by South and Central America with a 0.0% share in 2020, over the five-year and ten-year averages of 1.7% and 2.0% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

The US was the top country for non-industry sponsored Type 1 Diabetes (Juvenile Diabetes) trials, accounting for a 33.9% share in 2020, as against the five-year average of 26.3% and ten-year average of 28.2%.

Canada held a 10.2% share in 2020, over the five-year average of 9.9% and ten-year average of 8.1%, followed by India with an 8.5% share, compared with the five-year and ten-year averages of 3.5% and 2.4% respectively.

Japan held a 6.8% share in 2020, as against the five-year average of 4.4% and ten-year average of 6.6%.

Poland held a 5.1% share in 2020, over the five-year average of 0.8% and ten-year average of 1.4%.

Phase I trials lead industry sponsored clinical trials for Type 1 Diabetes (Juvenile Diabetes) in 2020

Phase I trials held a 47.5% share of industry sponsored clinical trials for Type 1 Diabetes (Juvenile Diabetes) in 2020, over the five-year average of 39.5% and ten-year average of 41.5%.

Phase II trials held a 32.2% share in 2020, as against the five-year average of 29.0% and ten-year average of 27.8%. Phase III trials held a 13.6% share in 2020, compared with the five-year and ten-year averages of 20.6% and 21.0% respectively.

Phase IV trials held a 6.8% share in 2020, over the five-year average of 10.9% and ten-year average of 9.7%.

Phase II trials lead non-industry sponsored clinical trials for Type 1 Diabetes (Juvenile Diabetes) in 2020

Phase II trials held a 54.0% share of non-industry sponsored clinical trials for Type 1 Diabetes (Juvenile Diabetes) in 2020, over the five-year average of 55.2% and ten-year average of 52.7%.

Phase IV trials held a 20.6% share in 2020, as against the five-year average of 21.9% and ten-year average of 22.8%. Phase I trials held a 15.9% share, compared with the five-year and ten-year averages of 11.4% and 12.2% respectively.

Phase III trials held a 9.5% share in 2020, over the five-year average of 11.6% and ten-year average of 12.2%.

Methodology: The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena